NBIX - Neurocrine Biosciences, Inc.
79.79 0.00 (0.00%)
After hours: 4:37PM EDT
| Previous Close | 78.52 |
| Open | 78.44 |
| Bid | 79.43 x 1100 |
| Ask | 79.96 x 800 |
| Day's Range | 77.51 - 80.15 |
| 52 Week Range | 64.72 - 126.98 |
| Volume | 387,216 |
| Avg. Volume | 898,727 |
| Market Cap | 7.284B |
| Beta (3Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.43 |
| Earnings Date | Jul 29, 2019 - Aug 2, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 107.14 |
- CNW Group•yesterday
AbbVie Launches ORILISSA™ (elagolix) 200 mg BID Dose for the Treatment of Moderate to Severe Pain Associated with Endometriosis
MONTREAL , May 21, 2019 /CNW/ - AbbVie (ABBV), a global, research and development-driven biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NBIX), announced that ORILISSA™ (elagolix) 200 mg twice daily is now available.
- PR Newswire•2 days ago
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
SAN DIEGO, May 20, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), demonstrating the effect of involuntary movements (possible TD) on patient health-related quality of life. Results from the study showed that involuntary movements had a significant negative impact on a patient's health-related quality of life, with nearly 30% of patients with possible TD reporting moderate-to-extreme problems performing their usual activities, including work, housework and leisure activities.
- PR Newswire•6 days ago
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
SAN DIEGO, May 16, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia (TD), an involuntary movement disorder. Neurocrine will also present new long-term data from the KINECT 4 Phase III, open-label study of INGREZZA® (valbenazine) capsules, highlighting the overall effect of treatment with INGREZZA on the abnormal movements associated with TD based on additional items from the Abnormal Involuntary Movement Scale (AIMS), including overall severity of abnormal movements, incapacitation due to abnormal movements and patient awareness of abnormal movements and distress level.
- PR Newswire•15 days ago
Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2019 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 14, 2019, in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com.
- Markit•15 days ago
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.77 billion over the last one-month into ETFs that hold NBIX are among the highest of the last year, but the rate of growth is slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire•16 days ago
Neurocrine Biosciences Honors Mental Health Month and Raises Awareness of Tardive Dyskinesia and its Impact on Patients
- Mental Health Advocacy Community Recognizes and 25 States Declare Tardive Dyskinesia Awareness Week as Part of Mental Health Month to Raise Prominence of Tardive Dyskinesia and Highlight the Impact on ...
- PR Newswire•17 days ago
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
SAN DIEGO and CAMBRIDGE, Mass., May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson's disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson's disease.
- PR Newswire•17 days ago
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations
SAN DIEGO, May 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced the presentation of a data analysis from two Phase III studies of opicapone, a novel, once-daily, oral, selective, peripherally-acting catechol-O-methyltransferase (COMT) inhibitor for the treatment of Parkinson's disease. The analysis found that treatment with opicapone 50 mg, added to levodopa, resulted in a significant and sustained increase in ON time without troublesome dyskinesia1, in Parkinson's disease patients with motor fluctuations. The analysis, which included data from more than 900 patients in the double-blind, placebo-controlled Phase III BIPARK-1 and BIPARK-2 studies, was highlighted as an oral session at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia.
- Thomson Reuters StreetEvents•20 days ago
Edited Transcript of NBIX earnings conference call or presentation 29-Apr-19 8:30pm GMT
Q1 2019 Neurocrine Biosciences Inc Earnings Call
- PR Newswire•22 days ago
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
- Long-Term Data from Two Phase III Trials Show INGREZZA Sustained Improvement in Tardive Dyskinesia Symptoms in Patients Taking Concomitant Medications for Psychiatric Disorders - Analysis of Phase III ...
- Market Realist•22 days ago
Neurocrine Biosciences Has Robust Late-Stage Pipeline
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Opicapone in Parkinson’s DiseaseIn its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug
- Market Realist•22 days ago
What Are Analysts Recommending for NBIX after Q1 Results?
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?Stock price movementsNeurocrine Biosciences (NBIX) reported first-quarter results on April 29. The company reported total revenues of $138.40 million, a YoY rise of 94.70%. Posted
- Benzinga•22 days ago
The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
Motley Fool•23 days agoNeurocrine Biosciences Inc (NBIX) Q1 2019 Earnings Call Transcript
NBIX earnings call for the period ending March 31, 2019.
- Associated Press•23 days ago
Neurocrine: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of $1.12 per share. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss ...
- PR Newswire•23 days ago
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $136.4 Million with Approximately 24,200 TRx Opicapone New Drug Application Submission Remains on Track for Q2 2019 Neurocrine Biosciences Plans ...
- American City Business Journals•26 days ago
Analysts point to potential Biogen M&A options after Alzheimer's failure
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
- Insider Monkey•last month
Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]
- Simply Wall St.•last month
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) A Financially Sound Company?
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Neurocrine Biosciences, Inc. (NASDAQ:NBIX), with a market cap of US$7.7b, are often out of the spotlight. While they are less talk...
- PR Newswire•last month
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
SAN DIEGO, April 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that it will report first quarter financial results after the Nasdaq market closes on Monday, April 29, 2019. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Participants can access the live conference call by dialing 877-876-9173 (US) or 785-424-1667 (International) using the conference ID: NBIX.
- GlobeNewswire•2 months ago
Recent Analysis Shows Coca-Cola, Neurocrine Biosciences, Worthington Industries, Lennox International, Barrett Business Services, and Balchem Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Market Realist•2 months agoAnalysts Raise Neurocrine Biosciences’ Target Price in March
Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.66% for Neurocrine Biosciences (NBIX) based on the company’s
- GlobeNewswire•2 months ago
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.
